Login to Your Account

Dermira wins again with Cimzia phase III; high dose conquers Enbrel

By Randy Osborne
Staff Writer

Thursday, January 19, 2017

Dermira Inc.’s third positive phase III trial with Cimzia in moderate to severe psoriasis turned up “market-leading type” results at the 400-mg dose, the firm’s chief development officer, Luis Peña, told BioWorld Today.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription